Aldosterone as a determinant of cardiovascular and renal dysfunction

Journal of the Royal Society of Medicine

Volumn 94, Issue 8, 2001, Pages 378-383

  Epstein, M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANDROGEN RECEPTOR; EPLERENONE; MINERALOCORTICOID RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; SPIRONOLACTONE;

ALDOSTERONE RELEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIAGNOSTIC VALUE; GYNECOMASTIA; HUMAN; HYPERTENSION; KIDNEY DISEASE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEXUAL DYSFUNCTION; WELLBEING;

EID: 0034896157     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107680109400803     Document Type: Review

References (49)

1. Recent progress in understanding aldosterone secretion
2. Aldosterone's effects and mechanism of action
3. Isolation of crystalline aldosterone from the urine of a nephrotic patient
4. On the biochemical mechanism of action of aldosterone
5. Mechanisms of action of mineralocorticoid hormones
6. Aldosterone and vascular damage
7. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
8. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats
9. Aldosterone and the hypertensive kidney: Its emerging role as a mediator of progressive renal dysfunction: A paradigm shift
10. Non-genomic actions of steroid hormones
11. Rapid cardiovascular action of aldosterone in man
12. Rapid non-genomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: Involvement of the Na+/H+ antiport
13. Non-genomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells
14. Looking beyond the dogma of genomic steroid action: Insights and facts of the 1990s
15. Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms
16. Mineralocorticoids, hypertension and cardiac fibrosis
17. Aldosterone: Intracellular receptors in human heart
18. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells
19. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor
20. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
21. Clinical characteristics of primary aldosteronism from an analysis of 145 cases
22. Cardiovascular complications in patients with primary aldosteronism
23. Reversing glomerular hypertension stabilizes established glomerular injury
24. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy
25. Understanding the nature of renal disease progression
26. Randomized placebo-controlled trial of effect of ramipril on decline in GFR and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
27. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
28. Role of aldosterone in the remnant kidney model in the rat
29. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level
30. Malignant hypertension resulting from deoxycortisone acetate and salt excess: Role of renin and sodium in vascular changes
31. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
32. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats
33. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
34. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
35. Local angiotensin II and transforming growth factor-beta 1 in renal fibrosis of rats
36. Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone spontaneously hypertensive rats
37. Effect of aldosterone on vascular angiotensin II receptors in the rat
38. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension
39. Remodeling and reparation of the cardiovascular system
40. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I
41. Long-term treatment of mineralocorticoid excess syndromes
42. Efficacy and tolerance of spironolactone in essential hypertension
43. Antialdosterones: Incidence and prevention of sexual side effects
44. Side-effects of spironolactone therapy in the hirsute woman
45. Tolerance of spironolactone
46. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension
47. Eplerenone
48. Aldosterone and cardiac hypertrophy: Effects of eplerenone on LV function and hypertrophic remodeling in LV pressure overload